BioCentury
ARTICLE | Clinical News

Tarceva erlotinib: Phase II

June 9, 2003 7:00 AM UTC

In an ongoing U.S. Phase II trial of Tarceva as monotherapy, 13 of 50 evaluable patients had a partial response. The median duration of response has not yet been reached. The trial is planned to enrol...